 |
 |
 |
 |
 |
 |
HIV-1 RNA, QN PCR |
|
|
copies/mL |
|
HIV-1 RNA, QN PCR |
|
|
Log copies/mL |
|
 |
 |
 |
 |
| PRIMARY |
| 1 |
Plasma EDTA |
3 (2.5) mL
|
Frozen - 35 Day(s)/Refrigerated - 5 Day(s)/Room Temperature - 24 Hour(s) |
|
| ALTERNATE |
| |
Plasma PPT Tube |
3 (2.5) mL
|
Refrigerated - 5 Day(s)/Frozen - 35 Day(s)/Room Temperature - 24 Hour(s) |
|
|
This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to assess patient prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment. The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on Raltegravir in clinical trials. Twenty three percent of patients receiving Raltegravir in a clinical trial experience virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
|
|
| Setup Schedule |
| Monday-Saturday |
| Reported (Analytical Time) |
|
Next day
|
|
CPT Code
|
87536
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
|
| Notes |
| If HIV-1 Viral load result is >400 copies/mL, then HIV-1 Integrase will be performed at an additional charge (CPT code: 87906) REJECT CRITERIA: Specimen collected using heparin as anticoagulant; Serum; Non-centrifuged PPT; Frozen PPT (in situ); Heparinized plasma; Gross hemolysis; Lipemia; leaking, uncapped or broken containers. |
|
